Source: Υπουργείο Υγείας (CY) Revision Year: 2021 Publisher: A. Menarini Industrie Farmaceutiche Riunite S.r.l., Via Sette Santi 3, 50131, Firenze Italy, Tel.: 0039 055 5680336
Pharmacotherapeutic group: Antivaricose therapy, Heparins or heparinoids for topical use
ATC code: C05BA03
Experimental pharmacological data demonstrate that Lioton 1000 gel administered by the percutaneous route exerts a marked antioedemigenic, antigranulomatous, antiexudative, antiinflammatory and anticoagulant activity.
Pharmacokinetic tests conducted in the rat have shown that heparin concentrations are detectable in the plasma for up to 24 hours after administration, with peak levels being reached after eight hours. Excretion is predominantly renal. Cutaneous administration of Lioton 1000 gel did not cause any alterations of coagulation parameters in man.
Acute toxicology tests conducted in the mouse and in the rat have demonstrated that Lioton 1000 gel has a very low s.c. and i.p. toxicity (LD50 2000 mg/kg). Subchronic and chronic treatment by the transcutaneous route has also shown the good local and systemic tolerability of the medicinal product.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
